274 related articles for article (PubMed ID: 37467536)
1. A place for biosimilars in the changing multiple sclerosis treatment landscape.
Greenberg B; Giovannoni G
Mult Scler Relat Disord; 2023 Sep; 77():104841. PubMed ID: 37467536
[TBL] [Abstract][Full Text] [Related]
2. Biosimilars in Oncology in the United States: A Review.
Nabhan C; Parsad S; Mato AR; Feinberg BA
JAMA Oncol; 2018 Feb; 4(2):241-247. PubMed ID: 28727871
[TBL] [Abstract][Full Text] [Related]
3. An overview of biosimilars and non-biologic complex drugs in Europe, the United States, and Canada and their relevance to multiple sclerosis.
Gran-Ruaz S; Mani A; O'Quinn S
Mult Scler; 2017 Dec; 23(14):1824-1829. PubMed ID: 29095099
[TBL] [Abstract][Full Text] [Related]
4. Capturing the holistic value of biosimilars in Europe - part 1: a historical perspective.
Mestre-Ferrandiz J; Czech M; Smolen JS; Cornes P; Aapro MS; Danese S; Deitch S; Tyldsley H; Foster W; Shah P; Latymer M; Vulto AG
Expert Rev Pharmacoecon Outcomes Res; 2024 Feb; 24(2):237-250. PubMed ID: 38175140
[TBL] [Abstract][Full Text] [Related]
5. Factors Affecting Health Care Provider Knowledge and Acceptance of Biosimilar Medicines: A Systematic Review.
Leonard E; Wascovich M; Oskouei S; Gurz P; Carpenter D
J Manag Care Spec Pharm; 2019 Jan; 25(1):102-112. PubMed ID: 30589628
[TBL] [Abstract][Full Text] [Related]
6. Rituximab biosimilars for lymphoma in Europe.
Jurczak W; Długosz Danecka M; Buske C
Expert Opin Biol Ther; 2019 Oct; 19(10):1045-1056. PubMed ID: 31512535
[No Abstract] [Full Text] [Related]
7. Clinical and regulatory perspectives on biosimilar therapies and intended copies of biologics in rheumatology.
Mysler E; Pineda C; Horiuchi T; Singh E; Mahgoub E; Coindreau J; Jacobs I
Rheumatol Int; 2016 May; 36(5):613-25. PubMed ID: 26920148
[TBL] [Abstract][Full Text] [Related]
8. Biosimilars in rheumatology: A review of the evidence and their place in the treatment algorithm.
Schulze-Koops H; Skapenko A
Rheumatology (Oxford); 2017 Aug; 56(suppl_4):iv30-iv48. PubMed ID: 28903543
[TBL] [Abstract][Full Text] [Related]
9. Identifying Key Benefits in European Off-Patent Biologics and Biosimilar Markets: It is Not Only About Price!
Dutta B; Huys I; Vulto AG; Simoens S
BioDrugs; 2020 Apr; 34(2):159-170. PubMed ID: 31792843
[TBL] [Abstract][Full Text] [Related]
10. Biosimilars to recombinant human FSH medicines: comparable efficacy and safety to the original biologic.
de Mora F; Fauser BCJM
Reprod Biomed Online; 2017 Jul; 35(1):81-86. PubMed ID: 28462793
[TBL] [Abstract][Full Text] [Related]
11. Leveraging the holistic benefits of biosimilars in Europe - part 2: how payers can safeguard the future of a healthy biosimilar market environment.
Mestre-Ferrandiz J; Czech M; Smolen JS; Cornes P; Aapro MS; Danese S; Deitch S; Tyldsley H; Foster W; Shah P; Latymer M; Vulto AG
Expert Rev Pharmacoecon Outcomes Res; 2024 Apr; 24(4):509-519. PubMed ID: 38284223
[TBL] [Abstract][Full Text] [Related]
12. Biosimilar medicines used for cancer therapy in Europe: a review.
Santos SB; Sousa Lobo JM; Silva AC
Drug Discov Today; 2019 Jan; 24(1):293-299. PubMed ID: 30244082
[TBL] [Abstract][Full Text] [Related]
13. Switching Reference Medicines to Biosimilars: A Systematic Literature Review of Clinical Outcomes.
Cohen HP; Blauvelt A; Rifkin RM; Danese S; Gokhale SB; Woollett G
Drugs; 2018 Mar; 78(4):463-478. PubMed ID: 29500555
[TBL] [Abstract][Full Text] [Related]
14. Biosimilar Agents for Psoriasis Treatment: The Perspective of Portuguese Patients.
Azevedo A; Bettencourt A; Selores M; Torres T
Acta Med Port; 2018 Sep; 31(9):496-500. PubMed ID: 30332374
[TBL] [Abstract][Full Text] [Related]
15. Biosimilars: From Production to Patient.
Sheridan M; Massich M; Ashourian N
J Infus Nurs; 2024 Jan-Feb 01; 47(1):19-29. PubMed ID: 38211611
[TBL] [Abstract][Full Text] [Related]
16. Biosimilars in ulcerative colitis: When and for who?
Ilias A; Gonczi L; Kurti Z; Lakatos PL
Best Pract Res Clin Gastroenterol; 2018; 32-33():35-42. PubMed ID: 30060937
[TBL] [Abstract][Full Text] [Related]
17. Biosimilars are coming: ready or not.
Zalcberg J
Intern Med J; 2018 Sep; 48(9):1027-1034. PubMed ID: 29984453
[TBL] [Abstract][Full Text] [Related]
18. Global Acceptance of Biosimilars: Importance of Regulatory Consistency, Education, and Trust.
Cazap E; Jacobs I; McBride A; Popovian R; Sikora K
Oncologist; 2018 Oct; 23(10):1188-1198. PubMed ID: 29769386
[TBL] [Abstract][Full Text] [Related]
19. Biosimilars: A Multidisciplinary Perspective.
Khraishi M; Stead D; Lukas M; Scotte F; Schmid H
Clin Ther; 2016 May; 38(5):1238-49. PubMed ID: 26988243
[TBL] [Abstract][Full Text] [Related]
20. Improving oncology biosimilar launches in the EU, the USA, and Japan: an updated Policy Review from the Southern Network on Adverse Reactions.
Bennett CL; Schoen MW; Hoque S; Witherspoon BJ; Aboulafia DM; Hwang CS; Ray P; Yarnold PR; Chen BK; Schooley B; Taylor MA; Wyatt MD; Hrushesky WJ; Yang YT
Lancet Oncol; 2020 Dec; 21(12):e575-e588. PubMed ID: 33271114
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
